Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin (2016 - 2026)

Aytu Biopharma has reported EBT Margin over the past 13 years, most recently at 69.79% for Q4 2025.

  • Quarterly EBT Margin fell 7215.0% to 69.79% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 38.7% through Dec 2025, down 3476.0% year-over-year, with the annual reading at 20.71% for FY2025, 478.0% down from the prior year.
  • EBT Margin was 69.79% for Q4 2025 at Aytu Biopharma, down from 14.15% in the prior quarter.
  • Over five years, EBT Margin peaked at 20.69% in Q1 2025 and troughed at 220.22% in Q1 2022.
  • The 5-year median for EBT Margin is 25.47% (2022), against an average of 43.18%.
  • Year-over-year, EBT Margin crashed -14801bps in 2021 and then surged 18855bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 49.95% in 2021, then soared by 49bps to 25.47% in 2022, then soared by 129bps to 7.46% in 2023, then plummeted by -68bps to 2.35% in 2024, then tumbled by -3064bps to 69.79% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBT Margin are 69.79% (Q4 2025), 14.15% (Q3 2025), and 128.46% (Q2 2025).